ClinicalTrials.gg
Status unknownNCT00415766Updated Jan 20, 2016

Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders

A Phase 4 interventional study of rHCG 250ug and uHCG 5000 IU in Infertility, sponsored by Eugonia. Status unknown at 1 site in Greece. Open to female participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-20.

Sponsored by Eugonia · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2016), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Infertility by Eugonia — none open to participants now, none under way, none of them phase 3. Infertility · Eugonia.

Enrollment
3rd of 10
150 · median 84
Started
2013
the only one that year
Phase 4
5 of 13
none open now
Registered
1st of 13
by date

Among the 13 studies in Infertility by Eugonia, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2013, is one of 5 in phase 4, and was the 1st registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 356 are open to participants now.

Browse Infertility studies →

Open to participants now

None of the 13 studies in Infertility by Eugonia is open now. The open studies under Infertility, anywhere →

Where they have run

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 39 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Infertility by Eugonia as a file.
02

Study summary

The purpose of this study is to compare the clinical outcomes of recombinant human chorionic gonadotrophin (rHCG) and urinary HCG (uHCG) in patients undergoing IVF cycles.

Read the detailed description

Urinary human chorionic gonadotrophin (u-hCG) has been widely used to induce final oocyte maturation and to trigger ovulation in assisted conception. Recombinant technology has allowed the production of r-hCG inj which all urinary contaminants are absent. Hence, this would allow the safe subcutaneous administration of a compound with less batch-to-batch variation. This study will investigate the effectiveness of the recombinant hCG compared to the currently used urinary hCG.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • recombinant hCG
  • urinary hCG
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 14 follicles >11mm on the day of triggering final oocyte maturation
  • Pretreated with GnRH antagonist protocol

Exclusion criteria

Exclusion Criteria:

  • Poor responders
  • Women with 25 or more follicles on the day of trigger
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Active comparator
    rHCG 250 ug

    Injection of 250 ug Ovitrelle to trigger final oocyte maturation

    Drug: rHCG 250ug

  • Active comparator
    uHCG 5000 IU

    Injection of 5000 IU Pregnyl to trigger final oocyte maturation

    Drug: uHCG 5000 IU

  • Active comparator
    uHCG 7500 IU

    Injection of 7500 IU Pregnyl to trigger final oocyte maturation

    Drug: uHCG 7500 IU

Interventions

  • DrugOvidrelStudies of OvidrelOvidrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Injection of 250 ug Ovitrelle to trigger final oocyte maturation

    Also known as: Ovitrelle

  • DruguHCG 5000 IU

    Injection of 5000 IU Pregnyl to trigger final oocyte maturation

    Also known as: Pregnyl 5000 IU

  • DruguHCG 7500 IU

    Injection of 7500 IU Pregnyl to trigger final oocyte maturation

    Also known as: Pregnyl 7500 IU

06

What researchers measure

Primary outcomes

  1. Percentage of mature oocytes

    Percentage MII/COCs

    Time frame: Day of oocyte retrieval (Day 0)

Secondary outcomes

  1. Positive test per embryo transfer

    Time frame: 15 days post oocyte retrieval

  2. Clinical pregnancy per embryo transfer

    Time frame: 7 weeks of gestation

  3. Ongoing pregnancy per embryo transfer

    Time frame: 12 weeks of gestation

  4. Level of serum hCG on day of oocyte retrieval

    Time frame: Day of oocyte retrieval

  5. Number of oocytes (COC) retrieved

    Time frame: Day of oocyte retrieval

  6. Number of mature oocytes (MII)

    Time frame: Day of oocyte retrieval

  7. Oocyte retrieval rate

    Number of oocytes retrieved/number of follicles on the day of triggering final oocyte maturation

    Time frame: Day of oocyte retrieval (Day 0)

  8. Incidence of severe early OHSS

    Time frame: up to Day 5 post oocyte retrieval

07

Study locations

1 site
  • Eugonia
    Athens, 11528, Greece
08

References and documents

Publications

  • Revelli A, Poso F, Gennarelli G, Moffa F, Grassi G, Massobrio M. Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis. Reprod Biol Endocrinol. 2006 Jul 18;4:38. doi: 10.1186/1477-7827-4-38. PubMed 16848893 ↗
  • Al-Inany HG, Aboulghar M, Mansour R, Proctor M. Recombinant versus urinary human chorionic gonadotrophin for ovulation induction in assisted conception. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003719. doi: 10.1002/14651858.CD003719.pub2. PubMed 15846677 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Dec 2015 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2006
First posted
Dec 25, 2006
Start
Jun 2013
Primary completionActual
Dec 2015
CompletionEst.
Jul 2016
Last update
Jan 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00415766
Lead sponsor
Eugonia
Responsible party
Sponsor
First posted
Dec 25, 2006
Start date
Jun 2013
Primary completion
Dec 2015
Completion
Jul 2016 (estimated)
Last update
Jan 20, 2016

Study contacts

Tryfon Lainas, PhD
principal investigator · Eugonia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ovidrel

Start the discussion